TRI Announces RBM Platform

Triumph Research Intelligence (TRI), based in London, UK and Raleigh, NC announces its Risk-Based Monitoring platform, Operational Platform for Review, Reporting and Analysis OPRA, for a combination of statistical calculations, data visualizations and operational activity management. In general terms, OPRA uses data from the systems where trial data is typically stored to search for patterns and outliers in the data. The patterns are displayed to users in easy to read graphs which show how each site relates to the others within a set of data. Combinations of patterns yield a “signature” that provides insight into the behavior of the site attending to patients in a clinical trial. Identifying these signatures allows users of OPRA to assess the risk that the site poses to the patients and to the trial based on seemingly unrelated data already collected from the site. TRI says the new platform addresses regulatory concerns around evidence that companies are providing quality management over their use of RBM.

Read the full release.